China’s pharmaceutical industry is undergoing rapid transformation, driven by China's drug regulatory reforms aimed at accelerating innovation, improving patient access, and aligning with global standards. As we approach 2025, three key Regulatory changes could reshape the market, impacting drug approvals, pricing, and commercialization strategies, especially for those navigating the drug approval process in China and adapting to evolving China pharmaceutical regulations.

Here’s what pharma companies, investors, and Regulatory professionals need to know: 

1. Expanded Use of Real-World Evidence (RWE) for Drug Approvals 

What’s Changing? 

China’s National Medical Products Administration (NMPA) is increasingly accepting Real-World Evidence (RWE) to support China drug approval, particularly for rare diseases, oncology, and post-marketing studies. In 2023, the Center for Drug Evaluation (CDE) released updated guidelines encouraging RWE in Regulatory decision-making to support both new and generic drug approval processes in China. 

Why It Matters in 2025? 

• Faster approvals for drugs targeting unmet medical needs. 
• Lower costs for clinical trials by supplementing (or replacing) traditional RCTs. 
• More flexible post-marketing requirements for innovative therapies. 

2. Stricter Enforcement of Good Pharmacovigilance Practices (GVP) 

What’s Changing?  

China’s Good Pharmacovigilance Practice (GVP) regulations, introduced in 2021, are now being strictly enforced, with heavy fines for non-compliance. The NMPA is increasing inspections of drug safety monitoring systems, especially for biologics, cell therapies, and imported drugs. 

Why It Matters in 2025? 

• Higher compliance costs for pharma companies (especially multinationals). 
• Mandatory safety updates for high-risk drugs (e.g., mRNA vaccines, gene therapies).
• Stronger integration with china clinical trial approval process protocols.
• Increased scrutiny of digital health platforms reporting adverse events. 

 3. Digitalization of Regulatory Submissions (eCTD Mandate) 

What’s Changing? 

China is moving toward mandatory electronic Common Technical Document (eCTD) submissions, following the U.S. FDA and EU model. A pilot program launched in 2023 is expected to evolve into a full requirement for all new drug approval applications in China by 2025.

Why It Matters in 2025? 

• Faster review times (NMPA targets 130-day approvals for priority drugs). 
• Harmonization with global standards, easing submissions for multinational companies. 
• Increased demand for regulatory tech (RegTech) solutions to manage eCTD workflows. 

Conclusion: How to Prepare for 2025 

1. For Innovators: Invest in RWE strategies to accelerate drug approval in China. 

2. For Compliance Teams: Strengthen pharmacovigilance systems to avoid GVP penalties. 

3. For Regulatory Professionals: Adopt eCTD-ready submission processes now to comply with evolving China eCTD mandates and broader China pharmaceutical regulations.

What’s Next? Prepare Today to Lead Tomorrow

As China moves toward a more innovation-friendly, compliance-driven, and digital Regulatory environment, companies that act now will be best positioned for success.

At Freyr, we help you stay ahead—by building strong RWE strategies, ensuring full GVP compliance, and managing seamless eCTD submissions in China tailored to NMPA requirements.

Contact us Today!